Last Updated: September 24, 2026

ASCOR Drug Patent Profile

Name: ASCOR Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Ascor, and what generic alternatives are available?

Ascor is a drug marketed by Mcguff, Fresenius Kabi Usa, and Stira. and is included in three NDAs.

The generic ingredient in ASCOR is ascorbic acid. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the ascorbic acid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ascor

A generic version of ASCOR was approved as ascorbic acid by FRESENIUS KABI USA on August 7^th, 2025.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ASCOR?
What are the global sales for ASCOR?
What is Average Wholesale Price for ASCOR?

Summary for ASCOR

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	152
Patent Applications:	3,589
Drug Prices:	Drug price information for ASCOR
What excipients (inactive ingredients) are in ASCOR?	ASCOR excipients list
DailyMed Link:	ASCOR at DailyMed

Drug patent expirations by year for ASCOR

Pharmacology for ASCOR

Drug Class	Vitamin C

US Patents and Regulatory Information for ASCOR

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mcguff	ASCOR	ascorbic acid	SOLUTION;INTRAVENOUS	209112-001	Oct 2, 2017	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Fresenius Kabi Usa	ASCORBIC ACID	ascorbic acid	SOLUTION;INTRAVENOUS	217131-001	Aug 7, 2025	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Stira	ASCORBIC ACID	ascorbic acid	SOLUTION;INTRAVENOUS	220172-001	Jul 30, 2026	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.